File downloaded on 2026-11-28
Source URL: https://medicines.health.europa.eu/veterinary/en/600000017453

Cevac MD Rispens concentrate and solvent for suspension for injection for chickens

Authorised

- Marek's disease virus, serotype 1, strain CVI-988 (Rispens, cell-associated), Live

Product identification

Medicine name:
Cevac MD Rispens concentrate and solvent for suspension for injection for chickens

Active substance:
Marek's disease virus, serotype 1, strain CVI-988 (Rispens, cell-associated), Live

Target species:
Chicken

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Marek's disease virus, serotype 1, strain CVI-988 (Rispens, cell-associated), Live
5000.00 plaque forming unit / 1.00 Dose

Pharmaceutical form:
Concentrate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Chicken**
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AD03

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Slovenia

Package description:
bag containing 1600 ml of solvent
bag containing 1200 ml of solvent
bag containing 1000 ml of solvent
bag containing 800 ml of solvent
bag containing 400 ml of solvent
bag containing 200 ml of solvent
1 ampoule containing 4000 doses
1 ampoule containing 2000 doses
1 ampoule containing 1000 doses

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Ceva-Phylaxia Zrt.

Marketing authorisation date:
12/08/2020

Manufacturing sites for batch release:
Ceva-Phylaxia Zrt.

Responsible authority:
Agency For Medicinal Products And Medical Devices Of The Republic Of Slovenia

Authorisation number:
DC/V/0712/001

Date of authorisation status change:
12/08/2020

Reference member state:
Spain

Procedure number:
ES/V/0312/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Sweden

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Package Leaflet

Combined File of all Documents

Labelling